You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Early promise for new immunotherapy combo in brain cancer

A combination treatment consisting of an experimental cancer drug – ipatasertib – and Roche’s immunotherapy agent Tecentriq (atezolizumab) has demonstrated early promise in an aggressive type of brain cancer.